Fluvastatin Sodium
Brand Names: Lescol Xl, Lescol
Methodology & AI Transparency ⓘ
Fluvastatin Sodium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Fluvastatin sodium extended-release tablets are indicated: ; To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease.
- 2 Real-world patient consensus: Tracked across 14 patient dosage logs with a 77% satisfaction benchmark (RxCUI 360507).
- 3 Typical cash cost range: Dispensing cost comparison spans $52.79 mail/discount cash up to $129.34 uninsured retail (federal NADAC $2.3088).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Fluvastatin Sodium: nausea (9.6%), dyspepsia (4.6%), headache (7.7%).
Ask our AI Specialists anything about Fluvastatin Sodium
Fluvastatin Sodium Mechanism, CYP450 Pathways & DailyMed Monograph
Fluvastatin sodium extended-release tablets are indicated: ; To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. ; As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. ; As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg of fluvastatin daily.
12.1 Mechanism of Action Fluvastatin is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Pharmacokinetic profiling of Fluvastatin Sodium demonstrates an elimination half-life of Approximately 9–20 hours terminal plasma half-life for Fluvastatin Sodium with ~29% systemic bioavailability (Fluvastatin Sodium) systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of fluvastatin sodium coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–2 hours post-dose for fluvastatin sodium.
Titration schedules for Fluvastatin Sodium (80 mg/1 Tablet, Extended Release → 80 mg/1 Tablet, Film Coated, Extended Release → 20mg Capsule → 40mg Capsule) require excluding fluvastatin sodium extended-release tablets are contraindicated in patients with:; acute liver failure or decompensated cirrhosis .; hypersensitivity to fluvastatin or any of the excipients in fluvastatin sodium extended-release tablets.; real-world patient logs highlight nausea (9.6% of reports), headache (7.7% of reports), dizziness (5.4% of reports) alongside a 77.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Fluvastatin Sodium (hmg-coa reductase inhibitor).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Fluvastatin Sodium dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Fluvastatin sodium extended-release tablets are contraindicated in patients with:
- Acute liver failure or decompensated cirrhosis .
- Hypersensitivity to fluvastatin or any of the excipients in fluvastatin sodium extended-release tablets.
Logged Side-Effect Incidence (14 Reports)
Fluvastatin Sodium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fluvastatin Sodium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Pravastatin for lowering Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. The Cochrane database of systematic reviews • 2023-09-18 • Meta-Analysis | Multi-cohort | 92/100 | PMID 37721222 ↗ |
| What the Latest Evidence Really Says About Comparative effectiveness and safety of statins as a class and of specific All statins showed statistically significant risk reduction of CVD and all-cause mortality in primary prevention populations while increasing the risk for some harm risks. American heart journal • 2019-04-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 30716508 ↗ |
| What the Latest Evidence Really Says About Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes Statins are effective medicines and confer benefit to patients in terms of primary and secondary prevention of coronary heart disease. BMC family practice • 2003-12-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 14969594 ↗ |
| What the Latest Evidence Really Says About Effect of different types of statins on kidney function decline and proteinuria: 1-year statin use versus control attenuated the progression of kidney function decline and proteinuria. Scientific reports • 2019-11-12 • Meta-Analysis | Multi-cohort | 86/100 | PMID 31719617 ↗ |
Fluvastatin Sodium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3088/unit (~$69.26/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $52.79 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $129.34 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $60.71 / mo | View logs ↓ |
Fluvastatin Sodium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fluvastatin Sodium RxNorm Concept ID | 360507 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3088 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $129.34 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $52.79 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 77.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fluvastatin Sodium Patient Community, Cohort Filters & Dosage Logs
Cross-verified Fluvastatin Sodium (hmg-coa reductase inhibitor) monograph synthesizing RxNorm 360507, openFDA FAERS signals, and $52.79–$129.34 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fluvastatin Sodium community threads and patient logs by age, biological sex, dosage, and treatment duration.